Factor XII (FXII) is a plasma protease that has emerged in recent years as a potential target to treat or prevent pathological thrombosis, to inhibit contact activation in extracorporeal circulation, and to treat the swelling disorder hereditary angioedema. While several protein based inhibitors with high affinity for activated FXII (FXIIa) were developed, the generation of small molecule inhibitors has been challenging.
Introduction
FXII, originally called Hageman factor, is a serine protease that plays an important role in the kallikreinkinin system and the intrinsic coagulation pathway. 1 It is expressed as an 80 kDa zymogen, primarily by hepatocytes, and circulates in plasma at a concentration of around 0.4 µM. FXII is converted into its activated form, FXIIa, by proteolytic cleavage between the heavy chain and the enzymatic light chain. This process is initiated when blood is exposed to negatively charged surfaces or compounds. FXIIa has the capacity to cleave factor XI, initiating the intrinsic coagulation pathway, and plasma kallikrein, activating the kallikrein-kinin system. 1 Activated plasma kallikrein can reciprocally activate FXII, leading to rapid activation of the contact system. FXIIa can also trigger the complement and fibrinolytic systems.
Human and animals deficient in FXII do not show abnormal bleeding from injury sites and have a normal hemostatic capacity. The physiological role of FXII and its benefit for individuals are not completely understood but are subject of active research. 2, 3 While the beneficial function of FXII for the body is currently not fully understood, more is known about its harmful role. FXII activity causes or contributes to a number of medical conditions leading to coagulation and/or inflammation. 4 The protease has received much attention in recent years due to its role in thrombosis. Mice deficient in FXII have a much reduced risk of thrombus formation and are protected from experimental ischemic stroke and pulmonary embolism. 5, 6 This observation and the limited role of FXII in hemostasis raised the prospect that inhibiting FXIIa could offer an antithrombotic therapy with low bleeding risk. The role of FXII in thrombosis has been confirmed in various experimental animal models, including rat, rabbit and baboon. 4 Several in vivo activators of the plasma contact system were reported, including platelet and bacterial polyphosphates, extracellular RNA and DNA, amyloid β peptide and misfolded proteins. 1 FXII also constitutes a constant threat in medical procedures that depend on extracorporeal circulation such as cardiopulmonary bypass surgery, extracorporeal membrane oxygenation (ECMO), or hemodialysis. 7, 8 In these procedures, contact with the materials of the medical devices, such 4 as tubing and membranes, can activate FXII and trigger the coagulation and inflammation pathways. FXII can also be activated by contact with catheters which can lead to catheter occlusion and thrombosis. 9 In hereditary angioedema (HAE), a life-threatening inherited swelling disease, FXIIa activates plasma kallikrein that in turn cleaves high-molecular-weight kininogen to release the vasoactive hormone bradykinin. 10 HAE type I and II result from a deficiency (type I) or malfunction (type II) of C1 esterase inhibitor, which is the main inhibitor of plasma kallikrein and FXII. In type III HAE, mutations in FXII cause recurrent edema attacks. 11 The important role of FXII in multiple diseases prompted academic laboratories and pharmaceutical companies to develop inhibitors of the protease. 4 A range of natural proteins that inhibit FXIIa with high affinity were identified and exploited to block FXIIa in experimental animal models. 4, 12, 13 Monoclonal antibodies either preventing activation of FXII or inhibiting the activated FXIIa were developed. 4 The humanized antibody 3F7 inhibited arterial and venous thrombosis in mouse and rabbit, and prevented coagulation in extracorporeal circulation in rabbits. 7 The antibody 15H8 blocked thrombosis in mice and baboon. 14 The development of small molecule FXIIa inhibitors has been challenging. The high structural similarity of FXII to numerous homologous trypsin-like serine proteases makes it difficult to generate selective inhibitors. 15, 16 Our laboratory has recently developed selective FXIIa inhibitors based on peptide macrocycles that have a relatively small size (< 2000 Da) and that are accessible to chemical synthesis. 17, 18 The best inhibitor reported is the bicyclic peptide 1 (FXII618; Figure 1a ), inhibiting FXIIa with a K i of 8.1 ± 0.7 nM and has a more than 2,000-fold selectivity over physiologically relevant homologous proteases. The peptide macrocycle inhibited the intrinsic coagulation pathway with an EC 2x for the activated partial thromboplastin time (aPTT) of around 3 µM, without affecting the prothrombin time (PT) at high concentrations (< 20% increase at 40 µM). We demonstrated that the inhibitor can be applied as a reagent for the inhibition of contact activation in diagnostic coagulation assays. 17 
5
For therapeutic application, a synthetic FXIIa inhibitor must block the protease with high affinity. In this work, we aimed at developing high affinity FXIIa inhibitors by improving the binding affinity of the above described bicyclic peptide 1. In the phage display selections that had been performed to isolate peptide 1, all of the bicyclic peptides that were screened contained exclusively natural amino acids.
Herein, we proposed to synthesize and screen variants of peptide 1 containing unnatural amino acids. In addition, we aimed at improving the stability of peptide 1 to prevent proteolytic degradation when the peptide is applied in vivo. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6
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Results and Discussion
Improving the inhibitory activity
Based on sequence similarities of peptides isolated in the phage selections against FXIIa, 17 the four amino acids of the first ring (Phe3, Arg4, Leu5, Pro6) and the middle two amino acids of the second ring of bicyclic peptide 1 (Gln9, Leu10) appeared to be most important for the binding (Figure 1a ). In a first attempt to improve the inhibitory activity of peptide 1, we chose to replace the amino acids in these positions with natural amino acids having similar side chains. Suitable amino acid substitutions were chosen using the two scoring matrices BLOSUM62 and PAM250 that indicate the evolutionary substitution probability of an amino acid by another one (Table 1) . To allow precise quantification of the synthesized peptides by absorption spectrometry, a tryptophan residue was appended to the C-terminus of all peptides. Peptide 1 with a C-terminal Trp, named peptide 2, had a K i of 10.2 ± 0.5 nM versus 8.1 ± 0.7 nM of the original peptide and thus a comparable activity. A total of 26 bicyclic peptides, each having one amino acid substituted in one of the six positions, were synthesized. While none of the peptides had an improved K i (Table 1) , valuable structure-activity relationship (SAR) data was obtained. In the position of Phe3, replacement of phenylalanine with tryptophan conserved the activity (peptide 3; K i = 12 ± 2). All other amino acid substitutions in this positon reduced the activity more than 2-fold (tyrosine, leucine, proline; peptides 4-6) or more than 10-fold (alanine, valine, isoleucine; peptides 7-9). In position Arg4, only the substitution to lysine was tested as this residue should have a positive charge to form an electrostatic interaction with Asp189 (trypsin numbering) at the bottom of the S1 binding pocket of FXIIa.
Lysine in this position reduced the inhibitory activity 10-fold (peptide 10; K i = 111 ± 8). In the position of Leu5, all substitutions, even those with amino acids closely resembling leucine such as valine (peptide 11) or isoleucine (peptide 12), reduced the affinity more than 50-fold. Peptides containing methionine (peptide 13) or alanine (peptide 14) in this position did not inhibit FXIIa at the highest concentration tested (3 µM).
In position Pro6, two of the amino acid replacements reduced the activity less than 2-fold, namely alanine (peptide 15) and leucine (peptide 18). In the second macrocyclic ring, all of the substitutions reduced the 7 activity of peptide 2 substantially. In positions Gln9 and Leu10, the smallest losses were seen for substitutions of aspartate (peptide 21, 54-fold) and isoleucine (peptide 26, 8-fold), respectively.
In a second attempt to improve the activity of peptide 1, we chose to replace the amino acids with unnatural residues that are structurally similar to the natural ones ( Table 2 ). In position Phe3, unnatural amino acids were tested resembling phenylalanine (peptides 29-32) and tryptophan (peptides 33-37), as peptides with these two natural amino acids were the most active (peptides 2 and 3). Two of the phenylalanine analogues reduced the binding affinity around 30-fold (peptides 29 and 30) and two of them did not inhibit FXIIa at the highest concentration tested (1 µM; peptides 31 and 32). Two out of the five peptides with tryptophan analogues had slightly improved activity: peptide 33 containing 2naphthylalanine had a 1.7-fold improved inhibitory activity (K i = 6.0 ± 0.6) and peptide 35 containing 3benzothienylalanine showed a 1.5-fold improvement (K i = 6.8 ± 1.8). In position Arg4, the amino acid was replaced with one lysine analogue (homolysine; peptide 38) and three arginine analogues (homoarginine, norarginine and 4-guanidinophenylalanine; peptides 39-41). All of these substitutions reduced the binding affinity of the peptide 5-fold or more. In the two positions Leu5 and Leu9, several aliphatic amino acids structurally resembling leucine were tested. All of the substitutions in position Leu5 greatly reduced the binding affinity wherein the smallest drop in affinity was found for norvaline (22-fold; peptide 42). In position Leu10, all the five unnatural amino acids reduced the affinity by less than 8-fold.
Many of the 48 peptide variants described above had substantially reduced activities, despite the fact that only one amino acid was replaced at a time and that most of the inserted amino acids were structurally similar to the substituted ones. In a third attempt to improve the inhibitory activity of peptide 1, we aimed for amino acid substitutions that would result in only small structural changes in the side chains. We chose to modify position Phe3 as this was the only site in which two substitutions with unnatural amino acids had yielded slightly improved inhibitors ( Table 3 ). The addition of a methyl group to the phenyl ring of 8 Phe3 in ortho-(peptide 51) and para-position (peptide 53) decreased the activity around 4-fold. In contrast, a methyl group in meta-position increased the affinity 2.7-fold (peptide 52; K i = 3.7 ± 0.2). This result indicated that some space around the side chain of phenylalanine is available but that the space is limited. We subsequently modified the phenyl ring of Phe3 by introducing heteroatoms or by halogenation, both modifications that conserved the size and shape of the amino acid side chain.
Replacement of a carbon atom with nitrogen in the phenyl ring in meta-position improved the activity around 3-fold (peptide 54; K i = 3.0 ± 0.1). The same substitution in para-position reduced the inhibitory activity around 6-fold (peptide 55). Substitution of hydrogen atoms on the phenyl ring with halogen atoms altered the activity dramatically in both directions. Fluorine in ortho-position reduced the activity around 2.5-fold (peptide 56). In contrast, fluorine in meta-and para-position enhanced the activity 2-and 11-fold, respectively (peptide 57: K i = 4.5 ± 0.4; peptide 58: K i = 0.89 ± 0.15). Bicyclic peptide 58 was the first synthetic FXIIa inhibitor with a subnanomolar inhibitory constant. We subsequently tested more electronegative atoms or groups in para-position. Iodine in this position reduced the activity 9-fold (peptide 59) and a nitro group improved the binding affinity 6-fold (peptide 60; K i = 1.64 ± 0.19). Finally, the peptide with the best inhibitory activity, peptide 58 containing a 4-fluorophenyl substitution in position Phe3, was synthesized without the C-terminal tryptophan that was introduced at the beginning to enable precise determination of the concentration based on absorption. The resulting peptide 61 (also termed FXII800), differing from peptide 1 only by the fluorine atom in phenylalanine, had a K i of 0.84 ± 0.03 nM and thus displayed an approximately 10-fold improvement in inhibitory activity (Table 4) .
Structural modeling and interactions of 4-fluoro-phenylalanine
The large affinity improvement achieved by only replacing a hydrogen atom with fluorine in Phe3 raised the question about the underlying molecular basis. In protein-ligand interactions, fluorine can strengthen binding affinities through direct interactions with proteins (e.g. polar interactions, hydrophobic effects) or by influencing other groups of the ligand that interact with the protein (e.g. change of pK a and thus Page 8 of 34 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 9 protonation state, change of electron distribution in an aromatic ring). 19, 20 We analyzed the environment of Phe3 in a structural model of the peptide 61 bound to FXIIa (Figure 1b ). The structure was obtained by simply replacing the hydrogen atom in the para position of Phe3 with fluorine in the previously developed model for the complex peptide 1:FXIIa (PDB file 'FXIIa-61_model' in Supporting Information). 17 The first macrocyclic ring of the bicyclic peptide containing the FRLP motif fits perfectly into the active site of 
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Improving the proteolytic stability
The stability of the FXIIa inhibitors can be assessed by incubating the bicyclic peptides in blood plasma and by subsequently measuring the remaining inhibitory activity in an assay with FXIIa and a fluorogenic substrate. Prior to this measurement, the plasma/bicyclic peptide samples were heat-inactivated to prevent cleavage of the fluorogenic substrate by other blood proteases or inhibition of FXIIa by blood-derived inhibitors. The assay quantifies not only the activity of intact bicyclic peptide but also the activity of potential metabolic products. Bicyclic peptide 1 was found to be inactivated by proteolysis when incubated in human plasma at 37 °C for extended time periods (t 1/2 = 4 ± 2 h). While a half-life of four hours is sufficient to block contact activation in vitro in coagulation assays, as demonstrated in our previous work, 17 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 10 330 ± 30 nM (peptide 62) and 9.3 ± 0.6 nM (peptide 63), respectively (Table 4 ). This result suggested that plasma proteases clip off the arginine at the N-terminus. To improve the stability, we searched for amino acid substitutions in position Arg1 that i) do not reduce significantly the binding affinity, and ii) prevent proteolytic cleavage of the first amino acid. Bicyclic peptides containing substitutions in position Arg1 were synthesized without the C-terminal tryptophan residue (Table 5 ). Natural amino acids such as isoleucine, valine and alanine in place of Arg1 all reduced the affinity > 5-fold (peptides 64-66).
Replacement with lysine conserved the binding affinity (peptide 67; 9.0 ± 0.9 nM), suggesting that a positive charge in the side chain is important. D-arginine reduced the binding affinity 3-fold (peptide 68; K i = 34.4 ± 0.7 nM). Based on this structure-activity data, we tested a number of unnatural amino acids carrying positively charged side chains (peptides 69-72). These peptides had a comparable or slightly reduced affinity, with K i value between 6.5 and 15 nM.
Next, we tested the stability of the bicyclic peptides 69-72, using the assay described above ( Table 5 ).
Plasma proteases were heat-inactivated by incubating the samples at 65 °C for 20 minutes. The heattreatment did not affect the activity of the bicyclic peptides. Two of the four peptides had an improved stability compared to peptide 1 (Figure 2a ). The longest half-life, 22 ± 3 h and thus a 5.5-fold improved stability compared to peptide 1, was found for peptide 71 which has a norarginine residue at the Nterminus. Finally, we combined the norarginine substitution with the amino acid replacement that most improved the inhibitory activity of peptide 1 (4-fluoro-phenylalanine in position 3 of the peptide). The resulting peptide 73, also termed FXII801, had a K i of 1.63 ± 0.18 nM and a plasma half-life of 16 ± 4 h.
Target selectivity
The target selectivity of peptide 73 was assessed by measuring the inhibition of structurally related or functionally important proteases and compared to the specificity profile of peptide 1 (Figure 2b ). 17 Eight Page 10 of 34 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 of the ten proteases were inhibited by less than 20% at the highest inhibitor concentration tested (40 µM).
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Only two of the paralogous proteases were inhibited more than 50% by peptide 73 at the tested concentrations, namely trypsin (K i = 1.30 ± 0.01 µM) and plasma kallikrein (K i = 45.1 ± 1.5 µM). The same two proteases were also inhibited by the peptides 1 and 61 at similar extents. These results showed that the affinity towards FXIIa could be improved while the activity towards other proteases remained essentially unchanged. The new FXIIa inhibitor peptide 73 exhibits a good selectivity of 800-fold over trypsin (a protease that is not present in the blood) and at least a 27,000-fold selectivity over all of the other tested plasma proteases.
Inhibition of the intrinsic coagulation pathway
The ability to selectively suppress the intrinsic coagulation pathway was assessed in in vitro coagulation 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60
Conclusions
The binding affinity and proteolytic stability of a bicyclic peptide inhibitor of FXIIa were improved substantially by synthesizing and screening a library of around 70 variants of an existing peptide macrocycle. These variants were created by substituting structurally similar natural and unnatural amino acid analogues for various macrocycle residues. It was discovered that the inhibitory activity of the bicyclic peptide could be most improved with conservative mutations, such as replacing the atoms in the amino acid side chain with halogens or heteroatoms, which resulted in only small structural changes. The best affinity improvement, on the order of 10-fold, was achieved by replacing a hydrogen with a fluorine atom in para position of a phenylalanine side chain. The blood plasma half-life of the bicyclic peptide was improved around 5-fold by replacing the N-terminal arginine with an unnatural arginine analogue.
This work is the first study in which the activity and stability of a phage-selected bicyclic peptide was improved by systematically synthesizing and testing a large number of peptide macrocycle variants containing unnatural amino acids. The result shows that synthesizing several dozen bicyclic peptide variants is sufficient to identify a handful of substitutions that significantly improve the affinity or stability. Given that small structural changes most improved the inhibitory activity, it is recommended that future optimization of phage-selected bicyclic peptides should be performed by synthesizing variants with structurally conservative mutations.
The inhibition constants of the developed bicyclic peptides are several orders of magnitude better than any small molecule FXIIa inhibitor reported thus far. The FXIIa inhibitors effectively prolong aPTT while leaving PT unchanged. With their favorable binding properties and high stability, the peptide macrocycles will be valuable tools to study the biology of FXII and could be exploited as lead structures for the development of a therapeutic agent. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13
Experimental Section
Bicyclic peptide synthesis:
Peptides were synthesized in house by standard solid-phase peptide synthesis using Fmoc-protected amino acids and Rink Amide AM resin on a 0.03 mmol scale. Amino acids were coupled twice at 4-fold molar excess using HBTU (4 eq) and HOBt (4 eq) as coupling reagents and DIPEA (6 eq). Coupling of unnatural amino acids was performed manually by adding 2 eq of Fmoc-protected amino acid, 2 eq of HATU and 4 eq of DIPEA. All peptides synthesized have a free N-terminus and an amidated C-terminus.
Peptides were cleaved from the resin under reducing conditions (90% TFA, 2.5% H 2 O, 2,5% thioanisol, 2,5% phenol, 2.5% 1.2-ethanedithiol). Crude peptide at a concentration of 1 mM was reacted with 1. Figure S1 and S2 and Table S1 .
Concentration determination of peptide stock solutions
The concentration of peptide was determined by absorption spectrometry at 280 nm or by weighing the lyophilized peptide before dissolving in water, or both. For determining the concentration of peptides by absorption spectrometry, theoretical extinction coefficients (ε280) were calculated based on the presence Page 13 of 34 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 of tryptophan (ε = 5500 M -1 cm -1 ) and tyrosine (ε = 1490 M -1 cm -1 ). For determining the concentration of peptides by weighing, it was assumed that one trifluoroacetic acid molecule is bound per positive charge of the peptide. The concentration of peptides that contain unnatural amino acids absorbing UV light at 280 nm with unknown ε280, or that lack tryptophan or tyrosine, was determined by weighing.
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Protease inhibition assays
The inhibitory activity of bicyclic peptides was determined by incubation with proteases and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 15
The bicyclic peptides inhibit most likely, as the parent peptide 1, FXII in a competitive manner. The Figure S2 .
Structural model and structure analysis
A structural model of the peptide 61-FXIIa complex was obtained by modifying a model of bicyclic peptide 1 bound to FXIIa that was previously developed by homology modeling and molecular dynamics simulation as described in Baeriswyl, V. et al. 17 The hydrogen atom in the para position of Phe3 was substituted with fluorine using the 'Build' function of Pymol. The resulting model for peptide 61 bound to FXIIa is provided in the Supporting Information (PDB file FXIIa-61_model). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 16
Page 15 of 34
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
Plasma stability assays
Peptide (2 µl of 2 mM in H 2 O) was added to 398 µl human plasma (Innovative Research) to obtain a final peptide concentration of 10 µM. The mixture was incubated in a water bath at 37 °C. At different time points (0, 0.5, 1 , 2 , 4 , 8 , 12, 24 and 48 hr), samples of 30 µl were removed, diluted to 200 µl with aqueous buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 1 mM CaCl 2 ) and incubated for 20 min at 65 °C to inactivate plasma proteases. Control experiments showed that the bicyclic peptide remains functional during the protease-inactivation step. The peptide/plasma samples were stored at -20 °C until the residual inhibitory activity of the peptides was measured in a FXIIa inhibition assay. For the activity assay, the peptide/plasma samples were centrifuged for 5 min at 16,000 g and the supernatant was collected. Two-fold dilutions of the peptide/plasma samples were prepared (peptide concentration ranges from 0.5 nM to 0.5 µM) and the residual activity of 0.5 nM FXIIa with 50 µM Boc-Gln-Gly-Arg-AMC substrate was measured. IC 50 values were derived from the fitted curve using the equation indicated above.
Residual inhibition in % was calculated using the equation IC 50 , 0h /IC 50,xh *100 wherein IC 50 , 0h is the functional strength of the inhibitor at time point 0 and IC 50,xh the functional strength of inhibitor after one of the different plasma incubation periods mentioned above.
aPTT and PT coagulant activity measurements
Coagulation times (aPTT and PT) were determined in human plasma using a STAGO STart4 Coagulation analyzer (Diagnostica). Human single donor plasma was used (Innovative Research). For the extrinsic coagulation, 50 µl of plasma was placed in the incubating chamber of the instrument for 2 min at 37 °C.
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